News

Physical signs indicate impending death in cancer patients


 

References

Several physical symptoms may signal upcoming death in advanced cancer patients, said Dr. David Hui and his colleagues in the department of palliative care and rehabilitation medicine at the University of Texas MD Anderson Cancer Center, Houston.

In a study of 357 advanced cancer patients in palliative care, 203 of whom died, eight specific symptoms were associated with death within 3 days. These physical signs were nonreactive pupils (positive likelihood ratio [LR], = 16.7), decreased response to verbal stimuli (LR, 8.3), decreased response to visual stimuli (LR, 6.7), inability to close the eyelids (LR, 13.6), drooping of the nasolabial fold (LR, 8.3), hyperextension of the neck (LR, 7.3), grunting of vocal chords (LR, 11.8), and upper gastrointestinal bleeding (LR, 10.3), the authors reported.

“The use of these bedside physical signs individually or in combination may assist clinicians in making the diagnosis of impending death,” Dr. Hui and his associates wrote.

Read the full article in Cancer at doi:10.1002/cncr.29048.

Recommended Reading

Members of Congress urge physician pay for end-of-life counseling
MDedge Hematology and Oncology
Hydrocodone rescheduling takes effect Oct. 6
MDedge Hematology and Oncology
FDA approves new abuse-prevention labeling for extended-release Embeda
MDedge Hematology and Oncology
Automated support eases hospice patient, caregiver burden
MDedge Hematology and Oncology
‘Co-rounding’ decreases patient length of stay
MDedge Hematology and Oncology
Palliative tumor removal extends survival
MDedge Hematology and Oncology
Medicare beneficiaries in hospice care get better care, have fewer costs
MDedge Hematology and Oncology
FDA approves extended-release hydrocodone with abuse-deterrent features
MDedge Hematology and Oncology
NIH report on long-term opioid treatment cites lack of data, research needs
MDedge Hematology and Oncology
Rise in reports of pain, depression in last year of life in oncology patients
MDedge Hematology and Oncology